Indication and Important Safety Information | Full Prescribing Information
How does Somatuline® Depot (lanreotide)
Injection work?

Somatuline® Depot (lanreotide) Injection works to help your body control acromegaly by lowering the levels of both growth hormone and insulin-like growth factor-1 to levels in the normal range. To achieve this, Somatuline Depot mimics a substance that occurs naturally, known as somatostatin.

At normal levels, somatostatin controls the amount of growth hormone and growth factor in your system. This helps your bones and muscles grow at a normal pace, your body process food, and your cells reproduce.

When you take Somatuline® Depot (lanreotide) Injection, it reduces the excess growth hormone in your body in the same way that somatostatin does. And while natural somatostatin lasts only a short time in your body, Somatuline® Depot (lanreotide) Injection remains in your system for 28 days.

How to take Somatuline® Depot (lanreotide) Injection

Somatuline Depot is injected in a simple, easy injection process. Learn more about how easy it is to inject Somatuline® Depot (lanreotide) Injection.

Possible side effects of Somatuline® Depot (lanreotide) Injection

Like all other medications, Somatuline® Depot (lanreotide) Injection can cause side effects. Learn about possible side effects of Somatuline Depot.

Could Somatuline® Depot (lanreotide) Injection help you?

Last year Somatuline Depot helped over 6000 people with acromegaly,including three fictional, but typical, patients named Dave, Mark, and Karen. See if you're like Dave, or Mark, or Karen.

Indication and Important Safety Information

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).

For Full Prescribing Information, click here.